ACIU Stock Financial Analysis - AC Immune SA (NasdaqGM) Stock

Overview

AC Immune SA is a biopharmaceutical company based in Switzerland, primarily engaged in the research and development of novel therapies for neurodegenerative diseases, with a significant focus on Alzheimer’s disease, Parkinson’s disease, and Down syndrome. Leveraging its proprietary technology platforms, including SupraAntigen and Morphomer, the company is deeply involved in developing therapeutic and diagnostic products aimed at enhancing life quality and halting the progression of neurodegenerative diseases. Key projects include ACI-35.030 for Alzheimer's, designed to target pathological tau proteins, and semorinemab, a treatment aimed at moderate Alzheimer's disease. The company collaborates extensively with global pharmaceutical entities and academic institutions to advance its clinical programs.

Quality, Value, Momentum Scores

This card shows the Quality, Value, and Momentum scores for the company

Quality

The QualityScore is a proprietary scoring model that identifies high quality companies, based on cash generating efficiencies.

Value

Proprietary scoring model that ranks companies based on their relative valuation. Scores range from 0 to 100, with 100 being the most undervalued.

Momentum

Proprietary scoring model that ranks companies on their six-month momentum.

Fund Sentiment

The Fund Sentiment (fka Ownership) score is a proprietary quantitative model that ranks companies based on levels of ownership accumulation.

QVM

The QVM Score is a proprietary scoring model that combines Quality, Value, and Momentum into a single metric that ranks companies from 0 to 100.

Income Statement: Revenue, Operating Income, Net Income

The revenue for AC Immune SA as of June 30, 2025 is 28.92 MM.
The operating income for AC Immune SA as of June 30, 2025 is -50.11 MM.
The net income for AC Immune SA as of June 30, 2025 is -50.51 MM.

Period End (TTM)	Revenue (MM)	Operating Income (MM)	Net Income (MM)
2025-06-30	28.92	-50.11	-50.51
2025-03-31	28.30	-51.68	-52.08
2024-12-31	27.31	-52.38	-50.92
2024-09-30	40.97	-37.30	-39.86
2024-06-30	15.49	-60.04	-60.51
2024-03-31	14.80	-56.12	-54.58
2023-12-31	14.80	-53.62	-54.23
2023-09-30	0.00	-68.78	-68.24
2023-06-30	3.94	-66.78	-66.61
2023-03-31	3.94	-69.59	-69.42
2022-12-31	3.94	-70.85	-70.75
2022-09-30	3.93	-74.54	-73.28
2022-06-30		-80.61	-75.68
2022-03-31		-79.44	-75.11
2021-12-31		-79.01	-73.00
2021-09-30	0.94	-74.94	-71.22
2021-06-30	2.07	-74.21	-74.30
2021-03-31	3.15	-71.21	-70.97
2020-12-31	15.43	-61.26	-61.92
2020-09-30	15.35	-60.62	-61.87

Income Statement: EPS

The earnings per share basic for AC Immune SA as of June 30, 2025 is -0.50.
The earnings per share diluted for AC Immune SA as of June 30, 2025 is -0.50.

Period End (TTM)	Earnings Per Share Basic	Earnings Per Share Diluted
2025-06-30	-0.50	-0.50
2025-03-31	-0.52	-0.52
2024-12-31	-0.51
2024-09-30	-0.41	-0.41
2024-06-30	-0.65	-0.65
2024-03-31	-0.62	-0.62
2023-12-31	-0.64
2023-09-30	-0.81	-0.81
2023-06-30	-0.80	-0.80
2023-03-31	-0.83	-0.83
2022-12-31	-0.85
2022-09-30	-0.88	-0.88
2022-06-30	-0.94	-0.94
2022-03-31	-0.97	-0.97
2021-12-31	-0.97
2021-09-30	-0.98	-0.98
2021-06-30	-1.03	-1.03
2021-03-31	-0.99	-0.98
2020-12-31	-0.86
2020-09-30	-0.86	-0.86

Cash Flow: Operations, Investing, Financing

The cash from operating activities for AC Immune SA as of June 30, 2025 is -42.62 MM.
The cash from investing activities for AC Immune SA as of June 30, 2025 is 21.00 MM.
The cash from financing activities for AC Immune SA as of June 30, 2025 is -0.88 MM.

Period End (TTM)	Cash From Operating Activities (MM)	Cash From Investing Activities (MM)	Cash From Financing Activities (MM)
2025-06-30	-42.62	21.00	-0.88
2025-03-31	46.00	-78.70	-0.69
2024-12-31	65.84	-105.29	-1.12
2024-09-30	43.72	-78.18	40.10
2024-06-30	44.56	-71.38	40.73
2024-03-31	-42.58	-0.72	42.70
2023-12-31	-60.41	65.64	43.25
2023-09-30	-61.62	47.32	2.07
2023-06-30	-61.86	37.48	1.48
2023-03-31	-67.23	67.10	-0.57
2022-12-31	-73.57	23.76	-1.35
2022-09-30	-73.99	-2.92	27.54
2022-06-30	-74.95	1.71	32.01
2022-03-31	-71.49	-53.41	32.12
2021-12-31	-65.69	-53.66	40.75
2021-09-30	-67.22	-27.78	11.55
2021-06-30	-68.32	-12.53	7.37
2021-03-31	-67.17	27.75	7.28
2020-12-31	-59.52	28.33	-0.80
2020-09-30	-52.90	18.59	-0.35

Valuation Metrics : PE, PriceToBook, PriceToTBV

P/Book: The current closing price divided by the book value per share.

P/TBV: The current price divided by the tangible book value per share.

Period End (TTM)	p/e	P/Book	P/TBV
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30

Valuation Metrics : EBitToEv, EBit3YrAvgToEv

Period End (TTM)	EBIT/EV	EBIT (3y)/EV
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30

Management Effectiveness

The roa for AC Immune SA as of June 30, 2025 is -0.22.
The roe for AC Immune SA as of June 30, 2025 is -0.42.
The roic for AC Immune SA as of June 30, 2025 is -0.52.
The croic for AC Immune SA as of June 30, 2025 is -0.37.
The ocroic for AC Immune SA as of June 30, 2025 is 0.46.

Period End (TTM)	ROA	ROE	ROIC	CROIC	OCROIC
2025-06-30	-0.22	-0.42	-0.52	-0.37	0.46
2025-03-31	-0.30	-0.35	-0.43	-0.36	0.56
2024-12-31	-0.22	-0.25	-0.30	0.00	0.33
2024-09-30	-0.42	-0.48	-0.48	0.09	0.35
2024-06-30	-0.32	-0.36	-0.37	-0.00	-0.29
2024-03-31	-0.29	-0.32	-0.33	0.29	-0.37
2023-12-31	-0.33	-0.36	-0.53	-0.10	-0.48
2023-09-30	-0.31	-0.33	-0.47	-0.16	-0.44
2023-06-30	-0.32	-0.34	-0.47	-0.16	-0.44
2023-03-31	-0.30	-0.33	-0.45	-0.00	-0.43
2022-12-31	-0.36	-0.41	-0.38	-0.25	-0.38
2022-09-30	-0.37	-0.42	-0.38	-0.25	-0.38
2022-06-30	-0.36	-0.40	-0.37	-0.20	-0.36
2022-03-31	-0.32	-0.35	-0.35	-0.43	-0.33
2021-12-31	-0.30	-0.33	-0.31	-0.33	-0.37
2021-09-30	-0.28	-0.32	-0.39	-0.46	-0.36
2021-06-30	-0.27	-0.30	-0.39	-0.38	-0.36
2021-03-31	-0.25	-0.27	-0.34	-0.15	-0.32
2020-12-31	-0.21	-0.23	-0.28	-0.15	-0.27
2020-09-30	-0.20	-0.21	-0.26	-0.15	-0.22

Gross Margins

The gross margin for AC Immune SA as of June 30, 2025 is -1.24.
The net margin for AC Immune SA as of June 30, 2025 is -1.84.
The operating margin for AC Immune SA as of June 30, 2025 is -1.83.

Gross Margin: The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.

Net Margin: The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.

Operating Margin: The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.

Period End (TTM)	Gross Margin	Net Margin	Operating Margin
2025-06-30	-1.24	-1.84	-1.83
2025-03-31	-1.29	-1.86	-1.92
2024-12-31	-0.50	-0.97	-0.91
2024-09-30	-2.83	-3.91	-3.88
2024-06-30	-2.78	-3.69	-3.79
2024-03-31	-2.69	-3.66	-3.62
2023-12-31	-55,097.00	-68,238.00	-68,780.00
2023-09-30	-13.50	-16.93	-16.97
2023-06-30	-14.02	-16.93	-16.97
2023-03-31	-14.33	-17.64	-17.68
2022-12-31	-15.60	-18.63	-19.24
2022-09-30		-18.63	-19.24
2022-06-30
2022-03-31
2021-12-31	-60.56	-77.33	-83.70
2021-09-30	-27.32	-75.44	-79.39
2021-06-30	-27.32	-35.96	-35.92
2021-03-31	-17.29	-22.53	-22.61
2020-12-31	-2.86	-4.01	-3.97
2020-09-30	-2.79	-4.03	-3.95